Literature DB >> 6668316

Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4'-dihydroxyantipyrine.

M W Teunissen, J E Meerburg-van der Torren, N P Vermeulen, D D Breimer.   

Abstract

A rapid, selective and sensitive method was developed for the determination of antipyrine and its main metabolites in plasma, saliva and urine by an automated high-performance liquid chromatographic system. Using a MOS-Hypersil reversed-phase column with a phosphate buffer--acetonitrile mobile phase, baseline separation of antipyrine, its metabolites 3-hydroxymethylantipyrine, norantipyrine and 4-hydroxyantipyrine, and the internal standard, phenacetin, was achieved within 6 min. Factors regarding the accuracy and precision of the method and the stability of phase I metabolites during sample preparation are discussed, taking into account certain drawbacks of previously published methods. Based on the same chromatographic system a method was developed for the assay of 4,4'-dihydroxyantipyrine in urine. This compound is an important metabolite of antipyrine in the rat, representing 12.6 +/- 1.8% of the administered dose (n = 18).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6668316

Source DB:  PubMed          Journal:  J Chromatogr


  34 in total

1.  The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function.

Authors:  G Everson; K C Lasseter; K E Anderson; L A Bauer; R L Carithens; K D Wilner; A Johnson; R J Anziano; T A Smolarek; R Z Turncliff
Journal:  Br J Clin Pharmacol       Date:  2000       Impact factor: 4.335

2.  An examination of a possible pharmacokinetic interaction between nifedipine and antipyrine.

Authors:  T Edeki; A Johnston; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Disposition of antipyrine in patients with extensive metastatic liver disease.

Authors:  G M Robertz-Vaupel; K D Lindecken; T Edeki; C Funke; S Belwon; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172.

Authors:  A De Boer; J C Stiekema; M Danhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

5.  The effect of roxatidine acetate and cimetidine on hepatic drug clearance assessed by simultaneous administration of three model substrates.

Authors:  E Tanaka; K Nakamura
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

6.  The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates.

Authors:  H Sakai; S Kobayashi; K Hamada; S Iida; H Akita; E Tanaka; E Uchida; H Yasuhara
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

7.  Antipyrine metabolite formation and excretion in patients with chronic renal failure.

Authors:  M W Teunissen; D Kampf; I Roots; N P Vermeulen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.

Authors:  J Posner; M Danhof; M W Teunissen; D D Breimer; P D Whiteman
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

9.  Influence of cimetidine on steady state concentration and metabolite formation from antipyrine infused with a rectal osmotic mini pump.

Authors:  M W Teunissen; C H Kleinbloesem; L G de Leede; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women.

Authors:  K Groen; M A Horan; N A Roberts; R S Gulati; B Miljkovic; E J Jansen; V Paramsothy; D D Breimer; C F van Bezooijen
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.